Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma

Ramanjit Sihota, Rohit Saxena, H. C. Agarwal, Vikas Gulati

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: To compare latanoprost and timolol maleate as primary therapy in 60 eyes with chronic primary angle-closure glaucoma after a laser iridotomy. Methods: We performed a prospective, randomized, crossover study of 60 eyes of 30 patients with chronic primary angle-closure glaucoma after laser iridotomy. Patients were randomized to 2 groups: those taking latanoprost once daily or those taking timolol twice daily. Three months after treatment with the first drug, the second drug was substituted. The circadian rhythm of intraocular pressure (IOP) was recorded before the start of therapy, at 3 months, and at 7 months. The fourth month was the washout period for the first drug. Results: The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by 8.2 ± 2.0 mm Hg with latanoprost (P<.001) and by 6.1 ± 1.7 mm Hg with timolol (P=.01). The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes having morning and afternoon peaks of IOP. A total of 43 eyes (72%) of patients taking latanoprost and 26 (43%) on timolol achieved a reduction of more than 30% from baseline IOP. Conclusion: There were greater mean and peak IOP reductions achieved with 0.005% latanoprost once daily compared with 0.5% timolol twice daily.

Original languageEnglish (US)
Pages (from-to)185-189
Number of pages5
JournalArchives of Ophthalmology
Volume122
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

latanoprost
Angle Closure Glaucoma
Timolol
Intraocular Pressure
Lasers
Pharmaceutical Preparations
Circadian Rhythm
Cross-Over Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma. / Sihota, Ramanjit; Saxena, Rohit; Agarwal, H. C.; Gulati, Vikas.

In: Archives of Ophthalmology, Vol. 122, No. 2, 01.02.2004, p. 185-189.

Research output: Contribution to journalArticle

Sihota, Ramanjit ; Saxena, Rohit ; Agarwal, H. C. ; Gulati, Vikas. / Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma. In: Archives of Ophthalmology. 2004 ; Vol. 122, No. 2. pp. 185-189.
@article{0afe627ac7ad42f78374d67d2abf2da6,
title = "Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma",
abstract = "Objective: To compare latanoprost and timolol maleate as primary therapy in 60 eyes with chronic primary angle-closure glaucoma after a laser iridotomy. Methods: We performed a prospective, randomized, crossover study of 60 eyes of 30 patients with chronic primary angle-closure glaucoma after laser iridotomy. Patients were randomized to 2 groups: those taking latanoprost once daily or those taking timolol twice daily. Three months after treatment with the first drug, the second drug was substituted. The circadian rhythm of intraocular pressure (IOP) was recorded before the start of therapy, at 3 months, and at 7 months. The fourth month was the washout period for the first drug. Results: The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by 8.2 ± 2.0 mm Hg with latanoprost (P<.001) and by 6.1 ± 1.7 mm Hg with timolol (P=.01). The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes having morning and afternoon peaks of IOP. A total of 43 eyes (72{\%}) of patients taking latanoprost and 26 (43{\%}) on timolol achieved a reduction of more than 30{\%} from baseline IOP. Conclusion: There were greater mean and peak IOP reductions achieved with 0.005{\%} latanoprost once daily compared with 0.5{\%} timolol twice daily.",
author = "Ramanjit Sihota and Rohit Saxena and Agarwal, {H. C.} and Vikas Gulati",
year = "2004",
month = "2",
day = "1",
doi = "10.1001/archopht.122.2.185",
language = "English (US)",
volume = "122",
pages = "185--189",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma

AU - Sihota, Ramanjit

AU - Saxena, Rohit

AU - Agarwal, H. C.

AU - Gulati, Vikas

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Objective: To compare latanoprost and timolol maleate as primary therapy in 60 eyes with chronic primary angle-closure glaucoma after a laser iridotomy. Methods: We performed a prospective, randomized, crossover study of 60 eyes of 30 patients with chronic primary angle-closure glaucoma after laser iridotomy. Patients were randomized to 2 groups: those taking latanoprost once daily or those taking timolol twice daily. Three months after treatment with the first drug, the second drug was substituted. The circadian rhythm of intraocular pressure (IOP) was recorded before the start of therapy, at 3 months, and at 7 months. The fourth month was the washout period for the first drug. Results: The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by 8.2 ± 2.0 mm Hg with latanoprost (P<.001) and by 6.1 ± 1.7 mm Hg with timolol (P=.01). The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes having morning and afternoon peaks of IOP. A total of 43 eyes (72%) of patients taking latanoprost and 26 (43%) on timolol achieved a reduction of more than 30% from baseline IOP. Conclusion: There were greater mean and peak IOP reductions achieved with 0.005% latanoprost once daily compared with 0.5% timolol twice daily.

AB - Objective: To compare latanoprost and timolol maleate as primary therapy in 60 eyes with chronic primary angle-closure glaucoma after a laser iridotomy. Methods: We performed a prospective, randomized, crossover study of 60 eyes of 30 patients with chronic primary angle-closure glaucoma after laser iridotomy. Patients were randomized to 2 groups: those taking latanoprost once daily or those taking timolol twice daily. Three months after treatment with the first drug, the second drug was substituted. The circadian rhythm of intraocular pressure (IOP) was recorded before the start of therapy, at 3 months, and at 7 months. The fourth month was the washout period for the first drug. Results: The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by 8.2 ± 2.0 mm Hg with latanoprost (P<.001) and by 6.1 ± 1.7 mm Hg with timolol (P=.01). The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes having morning and afternoon peaks of IOP. A total of 43 eyes (72%) of patients taking latanoprost and 26 (43%) on timolol achieved a reduction of more than 30% from baseline IOP. Conclusion: There were greater mean and peak IOP reductions achieved with 0.005% latanoprost once daily compared with 0.5% timolol twice daily.

UR - http://www.scopus.com/inward/record.url?scp=0842305651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842305651&partnerID=8YFLogxK

U2 - 10.1001/archopht.122.2.185

DO - 10.1001/archopht.122.2.185

M3 - Article

C2 - 14769594

AN - SCOPUS:0842305651

VL - 122

SP - 185

EP - 189

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 2

ER -